Eurofins Scientific Stock Surpasses Key Technical Threshold Two Days Before Earnings Release
Eurofins Scientific climbs 3.08% this Wednesday morning, reaching 67.04 euros, amid a sharp rebound of the CAC 40, which is up by 4.28% during the session. The bioanalytical services specialist's stock now shows a weekly performance of nearly 7%, just two days ahead of its annual 2025 earnings publication.
At 67.04 euros, Eurofins Scientific is trading above the upper Bollinger Band limit set at 65.74 euros. This breach indicates a potential overbought technical signal, suggesting that the stock is significantly deviating from its recent average and could face short-term profit-taking. The price is also above its 50-day (65.45 euros) and 200-day (63.48 euros) moving averages, confirming a bullish momentum over medium and long-term horizons. However, the RSI at 54 remains in a neutral zone, away from the alert thresholds of 70 or 30, which moderates the tension signal identified on the Bollinger Bands. The next resistance level is at 68.16 euros: surpassing this level during the session could potentially open up new room for progression. Over one year, the stock has seen a notable increase of 45.74%, although it has lost 2.84% over the past three months.
Financial Calendar Sets Stage for Crucial Earnings Announcement
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Eurofins Scientific's financial calendar schedules the release of its annual 2025 results on Friday, April 10, just two days away. This imminent deadline serves as a major catalyst for the stock, with traders positioning themselves ahead of this key disclosure. The general assembly is also scheduled for April 23. In the health and life sciences sector, comparables Sanofi and UCB are up by 1.09% and 0.99% respectively during the session, which are significantly lower than that of Eurofins. The stock's low beta (0.06) also indicates a historically very limited correlation with the overall market, suggesting that today's rise is more due to factors specific to the company—particularly the anticipation of results—than to the general rebound of European indices.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Contexte
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
Les informations présentées dans cet article sont fournies à titre purement indicatif et ne constituent en aucun cas une recommandation d'investissement, une incitation à acheter ou vendre un actif financier, ni un conseil en placement. Le lecteur est invité à réaliser ses propres recherches avant toute décision.
Les investissements en bourse comportent des risques, notamment de perte en capital. La performance passée d'un actif ou d'un marché ne présage en rien de ses performances futures. Toute décision d'investissement doit être prise en tenant compte de votre situation financière personnelle, de vos objectifs et de votre tolérance au risque.